ES8602407A1 - Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado - Google Patents
Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratadoInfo
- Publication number
- ES8602407A1 ES8602407A1 ES533901A ES533901A ES8602407A1 ES 8602407 A1 ES8602407 A1 ES 8602407A1 ES 533901 A ES533901 A ES 533901A ES 533901 A ES533901 A ES 533901A ES 8602407 A1 ES8602407 A1 ES 8602407A1
- Authority
- ES
- Spain
- Prior art keywords
- component
- cefaclor
- enteric
- release
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 title abstract 14
- 229960005361 cefaclor Drugs 0.000 title abstract 14
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 5
- 229920002261 Corn starch Polymers 0.000 abstract 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 5
- 229920002472 Starch Polymers 0.000 abstract 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 5
- 229930006000 Sucrose Natural products 0.000 abstract 5
- 239000002702 enteric coating Substances 0.000 abstract 5
- 238000009505 enteric coating Methods 0.000 abstract 5
- 239000008101 lactose Substances 0.000 abstract 5
- 235000010355 mannitol Nutrition 0.000 abstract 5
- 239000005720 sucrose Substances 0.000 abstract 5
- 229940100445 wheat starch Drugs 0.000 abstract 5
- 239000000654 additive Substances 0.000 abstract 4
- 230000000996 additive effect Effects 0.000 abstract 4
- 239000008120 corn starch Substances 0.000 abstract 4
- 229940099112 cornstarch Drugs 0.000 abstract 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
FABRICACION DE UNA FORMULACION DE LARGA DURACION DE UN DERIVADO CEFALOSPORANICO. COMPRENDE UN COMPONENTE DE LIBERACION RAPIDA Y OTRO DE LIBERACION LENTA, PARA ASI CONSEGUIR UNA LIBERACION PROLONGADA, EN PROPORCION ENTRE 3:7 HASTA 5:5, DE TAL FORMA QUE EL COMPONENTE DE LIBERACION LENTA EN FORMA DE PARTICULAS RECUBIERTAS CON UN FILM ENTERICO POLIMERICO SOLUBLE A UN PH ENTRE 5 Y 7, ES ROCIADO CON EL COMPONENTE DE LIBERACION RAPIDA, SIENDO DICHOS COMPONENTES CEFACLOR(3-CLORO-7-D) (2-FENILGLICINAMIDO)-3-CEFEM-4-CARBOXILICO MONOHIDRATO). EL COMPONENTE DE LIBERACION LENTA Y EL DE LIBERACION RAPIDA SON PREPARADOS SEPARADAMENTE Y LUEGO INTRODUCIDOS POR LLENADO EN UNA CAPSULA DURA Y SOLUBLE COMO FORMA UNITARIA DE DOSIFICACION. ANTIBIOTICO DE AMPLIO ESPECTRO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58108289A JPS601128A (ja) | 1983-06-15 | 1983-06-15 | 作用持続型セフアクロル製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES533901A0 ES533901A0 (es) | 1985-12-01 |
ES8602407A1 true ES8602407A1 (es) | 1985-12-01 |
Family
ID=14480890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES533901A Expired ES8602407A1 (es) | 1983-06-15 | 1984-06-15 | Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado |
Country Status (23)
Country | Link |
---|---|
US (1) | US4713247A (es) |
EP (1) | EP0129382B1 (es) |
JP (1) | JPS601128A (es) |
KR (1) | KR910004573B1 (es) |
AT (1) | ATE56869T1 (es) |
AU (1) | AU568654B2 (es) |
BG (1) | BG60261B2 (es) |
CA (1) | CA1213218A (es) |
DD (1) | DD216163A5 (es) |
DE (1) | DE3483282D1 (es) |
DK (2) | DK291884A (es) |
ES (1) | ES8602407A1 (es) |
FI (1) | FI84556C (es) |
GB (1) | GB2141342B (es) |
GR (1) | GR81598B (es) |
HU (1) | HU193434B (es) |
IE (1) | IE58278B1 (es) |
IL (1) | IL72083A (es) |
NZ (1) | NZ208345A (es) |
PH (1) | PH19902A (es) |
PT (1) | PT78699B (es) |
RO (1) | RO88924A (es) |
ZA (1) | ZA844357B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229132A (en) * | 1985-02-22 | 1993-07-20 | Grimberg Georges Serge | Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time |
JPS61210025A (ja) * | 1985-03-14 | 1986-09-18 | Teisan Seiyaku Kk | 安定化された抗生物質複合顆粒製剤 |
AU591248B2 (en) * | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
JPS62226926A (ja) * | 1986-03-27 | 1987-10-05 | Teisan Seiyaku Kk | 持続性複合顆粒剤 |
JPH0714863B2 (ja) * | 1986-06-02 | 1995-02-22 | 忠生 白石 | 時差溶解性の入浴剤 |
NZ223619A (en) * | 1987-02-27 | 1990-10-26 | Lilly Co Eli | Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
BE1002079A4 (fr) * | 1988-07-01 | 1990-06-19 | S M B Lab | Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation. |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5122384A (en) * | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
CA2085342A1 (en) * | 1990-06-14 | 1991-12-15 | Milton R. Kaplan | Stable aqueous drug suspensions |
GB9318641D0 (en) * | 1993-09-08 | 1993-10-27 | Edko Trading Representation | Compositions |
ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
AU5107496A (en) * | 1996-03-13 | 1997-10-01 | Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh | Medicament preparation for angiotensin converting enzyme (ace)-inhibitors |
US5948440A (en) * | 1997-12-17 | 1999-09-07 | Ranbaxy Laboratories Limited | Modified release matrix formulation of cefaclor and cephalexin |
ZA98728B (en) * | 1998-01-29 | 1998-10-28 | Ranbaxy Lab Ltd | Modified release matrix formulations of cefactor and cephalexin |
KR100296413B1 (ko) * | 1998-04-01 | 2001-11-14 | 김선진 | 세파클러함유서방성정제 |
EP1191924A4 (en) * | 1999-04-06 | 2005-02-09 | Pharmaquest Ltd | PHARMACEUTICAL PHARMACEUTICAL FORM FOR PULSED ADMINISTRATION OF (D-THREO) METHYLPHENIDATE AND ANOTHER CNS STIMULATING SUBSTANCE |
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
EP1180022A4 (en) * | 1999-05-14 | 2004-01-07 | Lilly Co Eli | PROCESS FOR THE MASS PRODUCTION OF PHARMACEUTICAL MATERIAL WITH UNIFORM SOLUBILITY |
US6596307B1 (en) | 1999-06-15 | 2003-07-22 | Eli Lilly And Company | Process for preparing pharmaceutical bulk material having uniform dissolution |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
CA2400818C (en) * | 2000-02-24 | 2009-01-06 | Advancis Pharmaceutical Corporation | Antibiotic and antifungal compositions |
WO2001062229A1 (en) * | 2000-02-24 | 2001-08-30 | Advanced Pharma, Inc. | Therapeutic product, use and formulation thereof |
CA2399856C (en) * | 2000-02-24 | 2009-01-27 | Edward M. Rudnic | Antibiotic composition with inhibitor |
WO2002056867A2 (en) * | 2001-01-18 | 2002-07-25 | Natco Pharma Limited | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
CA2478121A1 (en) * | 2002-03-07 | 2003-09-18 | Advancis Pharmaceutical Corporation | Antibiotic composition |
WO2003094899A1 (es) * | 2002-05-09 | 2003-11-20 | Diffucap-Chemobras Química E Farmacéutica, Ltda. | Nuevo procedimiento para la preparacion de composiciones de liberacion programada conteniendo (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, y al producto obtenido por dicho procedimiento |
JP2006528185A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2006528190A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2006528189A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
CA2535398C (en) * | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
JP2007513869A (ja) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
US20060233878A1 (en) * | 2003-09-30 | 2006-10-19 | Lupin Limited | Extended release formulation of beta-lactam antibiotics |
AU2006235483B2 (en) * | 2005-04-12 | 2010-11-25 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
US20060287212A1 (en) * | 2005-06-02 | 2006-12-21 | Novozymes A/S | Blends of inactive particles and active particles |
CN101188997A (zh) | 2005-06-02 | 2008-05-28 | 诺维信公司 | 非活性粒子和活性粒子的混合物 |
PT2391355T (pt) | 2009-05-19 | 2017-02-21 | Celgene Corp | Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolino-1,3-diona |
BR112014014805A2 (pt) * | 2011-12-19 | 2017-06-13 | Salix Pharmaceuticals Ltd | processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona |
CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
CN104688701A (zh) * | 2015-03-20 | 2015-06-10 | 江苏亚邦强生药业有限公司 | 一种头孢克洛片剂及其制备方法 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN110408670A (zh) * | 2019-08-19 | 2019-11-05 | 苏州盛达药业有限公司 | 一种酶催化合成头孢克洛的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
JPS52139713A (en) * | 1976-05-13 | 1977-11-21 | Shionogi & Co Ltd | Sustained release cefalexin preparations |
US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
GR74995B (es) * | 1980-08-27 | 1984-07-12 | Ciba Geigy Ag | |
JPS5826816A (ja) * | 1981-08-11 | 1983-02-17 | Teisan Seiyaku Kk | 球形顆粒からなる持続性複合顆粒剤 |
-
1983
- 1983-06-15 JP JP58108289A patent/JPS601128A/ja active Granted
-
1984
- 1984-05-30 US US06/615,242 patent/US4713247A/en not_active Expired - Lifetime
- 1984-05-31 NZ NZ208345A patent/NZ208345A/en unknown
- 1984-06-04 GR GR74913A patent/GR81598B/el unknown
- 1984-06-06 PT PT78699A patent/PT78699B/pt unknown
- 1984-06-08 EP EP84303908A patent/EP0129382B1/en not_active Expired - Lifetime
- 1984-06-08 GB GB08414633A patent/GB2141342B/en not_active Expired
- 1984-06-08 DE DE8484303908T patent/DE3483282D1/de not_active Expired - Fee Related
- 1984-06-08 ZA ZA844357A patent/ZA844357B/xx unknown
- 1984-06-08 IE IE144484A patent/IE58278B1/en not_active IP Right Cessation
- 1984-06-08 AT AT84303908T patent/ATE56869T1/de not_active IP Right Cessation
- 1984-06-11 PH PH30800A patent/PH19902A/en unknown
- 1984-06-13 FI FI842406A patent/FI84556C/fi not_active IP Right Cessation
- 1984-06-13 IL IL72083A patent/IL72083A/xx unknown
- 1984-06-13 BG BG65844A patent/BG60261B2/xx unknown
- 1984-06-13 RO RO84114861A patent/RO88924A/ro unknown
- 1984-06-14 DK DK291884D patent/DK291884A/da unknown
- 1984-06-14 DK DK291884A patent/DK170922B1/da not_active IP Right Cessation
- 1984-06-14 HU HU842312A patent/HU193434B/hu not_active IP Right Cessation
- 1984-06-15 KR KR1019840003359A patent/KR910004573B1/ko not_active IP Right Cessation
- 1984-06-15 ES ES533901A patent/ES8602407A1/es not_active Expired
- 1984-06-15 CA CA000456659A patent/CA1213218A/en not_active Expired
- 1984-06-15 AU AU29418/84A patent/AU568654B2/en not_active Ceased
- 1984-06-15 DD DD84264197A patent/DD216163A5/de unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8602407A1 (es) | Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado | |
US4740365A (en) | Sustained-release preparation applicable to mucous membrane in oral cavity | |
ES8800041A1 (es) | Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales | |
ATE217188T1 (de) | Granulierte pharmazeutische zusammensetzung | |
NO175240C (no) | Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler | |
DK164259C (da) | Farmaceutisk formulering til langsom frigivelse af den aktive bestanddel og fremgangsmaade til fremstilling af en saadan formulering | |
FI885460A0 (fi) | Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi | |
EP0217778A3 (en) | Galenical forms for the sustained release of verapamil, their preparation and medicaments containing them | |
AU563725B2 (en) | Oral controlled release multiple unit formulation | |
CA2016039A1 (en) | Extended release pharmaceutical formulations | |
AU6770490A (en) | Solid pharmaceutical compositions containing cimetidine | |
DE69816951D1 (de) | Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix | |
US4765988A (en) | Amosulalol hydrochloride long acting formulations | |
US3865935A (en) | Tableting of erythromycin base | |
JPH0157090B2 (es) | ||
GB1443923A (en) | Sustained release compositions | |
EP0602619A1 (en) | Controlled-release pharmaceutical compositions containing nicergoline | |
SE8701077L (sv) | Farmaceutisk beredning | |
PL180979B1 (pl) | Sposób wytwarzania karbamazepinowej postaci lekarstwa z opóźnionym uwalnianiem substancji biologicznie czynnej | |
EP0447168A2 (en) | Long acting granular pharmaceutical composition | |
ES2019024A6 (es) | Procedimiento de preparar una composicion farmaceutica a base de trimebutina. | |
JPS54126722A (en) | Slow release antibiotic tablet | |
JPS56142208A (en) | Prolongable prostaglandin transvaginal agent and its preparation | |
JPS5659707A (en) | Lasting antibiotic pharmaceutical and its preparation | |
KR0177191B1 (ko) | 테르페나딘 함유 펠렛 조성물 |